Engineered pagoda-like dissolvable microneedle patches for synergistic photothermal antibacterial and wound regenerative therapy Authors: Yukun Liu, Kang Wang, Xiaodong Liang, Zhen Gao, Zhanfei Li, Xiangjun Bai, Guoyun Wan, Yuchang Wang Published: 2026 ABSTRACT Background and objectiveDiabetic chronic wounds heal slowly due to persistent inflammation, impaired macrophage polarization, and compromised angiogenesis, while conventional therapies fail to effectively modulate the wound microenvironment. This study aimed to develop pagoda-like microneedle (MN) patches incorporating isoliquiritigenin (ISL)-loaded hollow mesoporous copper sulfide nanoparticles (HMCuS@ISL MNs) with near-infrared (NIR) photothermal functionality to achieve local immunometabolic regulation and promote angiogenesis, antibacterial activity, and wound repair.MethodsHMCuS@ISL nanoparticles were integrated into a collagen/hyaluronic acid matrix to form pagoda-like MN patches. Nanoparticles were characterized by TEM, DLS, and UV–vis–NIR spectroscopy, and their photothermal performance under 808 nm irradiation was evaluated. MN mechanical strength, dissolution, cytocompatibility, antibacterial activity, and in vitro angiogenesis were systematically assessed. ISL-mediated macrophage polarization was analyzed via RNA sequencing, qPCR, flow cytometry, and metabolic flux assays. In vivo efficacy and biosafety were evaluated in streptozotocin-induced diabetic mouse wound models.ResultsHMCuS@ISL nanoparticles displayed uniform hollow–mesoporous morphology with strong NIR absorption and efficient photothermal conversion. MN patches exhibited excellent mechanical strength, rapid dissolution, and good biocompatibility. ISL promoted M2 macrophage polarization by suppressing glycolysis and enhancing fatty acid oxidation. HMCuS@ISL MNs, especially under NIR irradiation, significantly enhanced fibroblast migration, angiogenesis, antibacterial activity, and accelerated wound closure. Histological and immunostaining analyses confirmed improved re-epithelialization, collagen deposition, vascularization, and immune microenvironment balance without systemic toxicity.ConclusionHMCuS@ISL MN patches integrating metabolic immune modulation with photothermal therapy provide an effective, safe, and minimally invasive strategy for diabetic wound healing.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s12951-026-04426-x. Introduction The skin, as the largest barrier organ of the body, plays a crucial role in defending against pathogens, maintaining fluid homeostasis, and regulating body temperature [1, 2]. However, trauma, burns, or chronic ulcers can compromise the skin barrier, leading to infection, inflammation, and tissue necrosis, which may be life-threatening in severe cases [3, 4]. In particular, under pathological conditions such as diabetes or severe infections, wound healing is markedly delayed, and conventional treatments, including dressing changes, antibiotics, or surgical debridement, often exhibit limited efficacy [5, 6]. Therefore, developing novel wound therapies that combine antibacterial, pro-healing, and microenvironment-modulating functions has become a research focus in tissue repair and regenerative medicine. Macrophages play a key role in immune regulation and tissue reconstruction during wound healing. In diabetic wounds, persistent hyperglycemia and oxidative stress maintain prolonged inflammatory signaling, preventing macrophages from transitioning from the pro-inflammatory M1 phenotype to the pro-repair M2 phenotype, thereby trapping the wound in a chronic inflammatory state [7]. M1 macrophages continuously secrete pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and interleukin-6 (IL-6), which impede angiogenesis and delay tissue repair [8, 9]. This phenotypic imbalance is closely linked to metabolic dysregulation: M1 macrophages rely on glycolysis to sustain inflammation, whereas M2 macrophages primarily utilize oxidative phosphorylation (OXPHOS) and fatty acid oxidation for energy [10, 11]. ISL, a bioactive compound derived from licorice root, exhibits diverse pharmacological activities, including anti-inflammatory and antioxidant effects [12–14]. In zebrafish wound models, ISL has been shown to suppress inflammation by regulating NF-κB p65 nuclear translocation [15] and the Raf/MEK signaling pathway [16]. Thus, ISL holds potential to promote macrophage M1-to-M2 polarization and accelerate diabetic wound healing. However, its clinical application is limited by rapid release and poor local retention. Microneedle (MN)-based transdermal delivery systems have attracted considerable attention for their ability to painlessly penetrate the stratum corneum, enabling localized and precise drug administration [17–19]. Compared with conventional topical or injectable formulations, MNs enhance drug penetration at the wound site while reducing systemic side effects [20, 21]. To further improve mechanical stability and promote rapid dissolution upon insertion, we designed a “pagoda-like” microneedle architecture. This stepwise structure increases the contact area between the microneedle body and the matrix material, thereby enhancing structural integrity and facilitating efficient drug distribution and release at the microneedle tips. Recently, MN systems combined with photothermal therapy (PTT) have drawn significant interest for the treatment of infected wounds. These systems typically exploit localized photothermal effects to achieve antibacterial activity and disrupt biofilms. However, most reported MN–PTT platforms focus primarily on physical antibacterial effects, with limited capacity to modulate persistent inflammation and immune dysregulation—critical pathological processes in diabetic wounds. Consequently, there is a need for multifunctional MN systems that can simultaneously provide antibacterial activity, immune regulation, and microenvironment remodeling for effective chronic wound therapy. Hollow mesoporous copper sulfide nanoparticles (HMCuS) offer a promising approach, as they can serve both as drug carriers and stabilizers, while generating photothermal effects under near-infrared (NIR) irradiation to kill bacteria [22–26]. Combining PTT with drug delivery thus represents a versatile strategy to achieve multifunctional wound management [27–29]. Based on this rationale, we developed a pagoda-like MN patch co-loaded with HMCuS nanoparticles and the small-molecule drug isoliquiritigenin (ISL). This system is designed to synergistically regulate the diabetic wound microenvironment through combined photothermal antibacterial activity and immune-metabolic modulation, providing a comprehensive strategy for chronic wound treatment. In this study, HMCuS were synthesized and loaded with ISL, then incorporated into a type I collagen/hyaluronic acid matrix to form pagoda-like dissolvable MNs. This system exhibits excellent biocompatibility, degradability, and sufficient mechanical strength to penetrate the epidermis and deliver ISL to deeper tissues. HMCuS@ISL nanoparticles not only retain the photothermal antibacterial function of HMCuS but also stabilize and provide sustained release of ISL, enabling metabolic reprogramming to enhance macrophage-mediated anti-inflammatory effects. Importantly, HMCuS@ISL MNs demonstrated potent antibacterial, anti-inflammatory, immunomodulatory, pro-angiogenic, and wound-healing effects in diabetic mouse models. Overall, this work provides a new strategy and experimental foundation for the application of intelligent photothermal-drug synergistic MN systems in wound repair. Materials and methods Materials and reagents Polyvinylpyrrolidone K30 (PVP-K30), copper(II) chloride (CuCl₂), and fluorescein isothiocyanate (FITC) were purchased from Heowns Biochem Technologies, LLC (Tianjin, China). Type I collagen was obtained from Beijing Jinming Biotechnology Co., Ltd. Hyaluronic acid (HA, ~ 50 kDa) and silicone microneedle molds (type STM-2) were purchased from Henan Micro-Nano BenTeng Biotechnology Co., Ltd. (Henan, China). Isoliquiritigenin (ISL, purity ≥ 98%) was obtained from Chengdu Master Biotechnology Co., Ltd. (Sichuan, China). All experimental water was double-distilled (DDW). Cell lines used included human umbilical vein endothelial cells (HUVECs), mouse fibroblasts (NIH-3T3), and RAW264.7 macrophages, purchased from ATCC. Male BALB/c mice (8 weeks old) were provided by the institutional animal center. All animal procedures were approved by the Institutional Animal Care and Use Committee and conducted according to relevant guidelines. CCK-8 assay kits were obtained from Proteintech (Wuhan, China), and Calcein/PI viability kits from Beijing Biotium (Shanghai, China). Matrigel matrix was obtained from Corning (New York, USA). SYTO9/propidium iodide (PI) staining kits were obtained from Tianjin Tianjin Biotech Co., Ltd. Primary antibodies against HK1, HK2, PFKP, PKM, SLC2A1, and CPT1A were purchased from ABclonal (Wuhan, China). Flow cytometry antibodies CD86 and CD206 were obtained from BioLegend (San Diego, USA). Synthesis of HMCuS nanoparticles Hollow mesoporous copper sulfide (HMCuS) nanoparticles were synthesized as follows: 1920 mg of PVP-K30 was dissolved in 200 mL DDW, followed by the addition of 800 µL of 67.225 mg/mL CuCl₂ solution under stirring. Subsequently, 1 mL of 0.1 M NaOH was added, adjusting the pH to 9. The mixture was stirred at room temperature for 2 min. Then, 102.4 µL of 40% hydrazine hydrate was added, and the mixture was stirred for 5 min. Next, 1600 µL of 985 mg/mL Na₂S·9 H₂O solution was added, and the reaction was continued at 60 °C and 1000 rpm for 2 h. The product was centrifuged at 11,000 rpm for 10 min, the supernatant discarded, and the pellet was resuspended in 10 mL DDW using ultrasonication. The centrifugation and washing steps were repeated, followed by resuspension in 500 µL DDW and lyophilization to obtain HMCuS powder. Preparation of HMCuS@ISL nanocomposites To prepare HMCuS@ISL, 2 mg of HMCuS was dispersed with 400 µg of ISL in 500 µL DDW and stirred at room temperature for 12 h. During this process, 2 mg of PEG was added to enhance the aqueous solubility of HMCuS. The mixture was centrifuged at 11,000 rpm for 10 min, and the precipitate was resuspended in DDW to obtain HMCuS@ISL solution. Fabrication of HMCuS@ISL microneedle patches HMCuS@ISL solution (2 mg/mL) was mixed with 40% type I collagen and stirred until fully dissolved. Then, 15% HA (MW 30–50 kDa) was added and stirred to obtain a homogeneous solution. The solution was cast into silicone microneedle molds and centrifuged for 5 min, followed by recovery and drying at 35 °C for 30 min. The process was repeated, followed by drying for 36 h. The microneedle patches were then demolded to yield HMCuS@ISL MNs. Characterization of HMCuS and HMCuS@ISL nanoparticles The morphology and size of HMCuS and HMCuS@ISL were characterized by transmission electron microscopy (TEM). Dynamic light scattering (DLS) was used to determine particle size and zeta potential. UV–Vis–NIR spectrophotometry was employed to record the absorption spectra of HMCuS and HMCuS@ISL (100 µg/mL). Characterization of HMCuS@ISL microneedle patches Microneedle morphology was observed under an optical microscope. HMCuS@FITC MNs, prepared by substituting ISL with FITC, were imaged under a fluorescence microscope to evaluate drug distribution uniformity. The penetration capability of MNs was tested by inserting them into mouse skin. Mechanical properties were measured using a texture analyzer to obtain force–displacement curves. Dissolution behavior was examined by applying HMCuS@ISL MNs to mouse skin and removing them at 0, 1, 3, 5, and 8 min for microscopic observation. Fluorescence microscopy revealed that the drug-loaded nanoparticles were highly concentrated at the microneedle tips (approximately 30% of the needle volume) and exhibited a uniform distribution. This “pagoda-like” design effectively minimized drug retention at the base, ensuring that the vast majority of ISL was delivered into the subcutaneous tissue along with the microneedle tips. Photothermal evaluation of HMCuS and HMCuS@ISL Solutions of HMCuS (50, 100, 150, 300 µg/mL) were irradiated with an 808 nm laser at 0.8 W/cm², and temperature changes were recorded over 10 min. HMCuS and HMCuS@ISL (150 µg/mL) solutions were similarly irradiated, and temperature evolution was monitored using a near-infrared thermal imaging system. In vitro antibacterial activity The antibacterial activity of the microneedle patches was evaluated using both the plate spread method and colony counting. Escherichia coli (E. coli, ATCC 25922) and Staphylococcus aureus (S. aureus, ATCC 29213) were used as representative Gram-negative and Gram-positive bacteria, respectively. Bacterial suspensions were diluted to 1 × 10³ CFU/mL, and 100 µL of each suspension was evenly spread onto Luria-Bertani (LB) agar plates. Samples from different treatment groups (blank MNs, HMCuS MNs, HMCuS@ISL MNs, and HMCuS@ISL MNs + NIR) were placed at the center of each plate and incubated for 6 h. For the NIR group, samples were irradiated with an 808 nm laser (1 W/cm², 5 min) prior to continued incubation. Subsequently, bacterial suspensions were serially diluted and spread onto nutrient agar plates, incubated at 37 °C for 24 h, and colony-forming units (CFUs) were counted. Bacterial viability was further assessed using SYTO9/propidium iodide (PI) dual staining. Briefly, bacterial suspensions (~10⁶ CFU/mL) were incubated with SYTO9 and PI dye mixture (1:1, v/v) for 15 min at room temperature in the dark. Fluorescence microscopy was used to observe the stained bacteria: live bacteria with intact membranes exhibited green fluorescence (SYTO9), while membrane-compromised or dead bacteria emitted red fluorescence (PI). Cell viability assay HUVECs and NIH-3T3 cells were seeded in 96-well plates at a density of 1 × 10⁴ cells/well and treated with extract solutions from each microneedle group for 1, 3, or 5 days. Cell viability was assessed using the CCK-8 assay according to the manufacturer’s instructions. Live/dead cell staining After 24 h of treatment, cells were subjected to Calcein-AM/PI dual staining for live/dead assessment. Culture medium was removed, and 300 µL of Calcein-AM/PI staining solution was added per well. Cells were incubated at 37 °C with 5% CO₂ for 15 min in the dark, followed by imaging using a confocal laser scanning microscope (Leica SP5, Leica Camera AG, Germany). Scratch wound healing assay HUVECs were cultured in 6-well plates until confluence. A sterile pipette tip was used to create a linear scratch, after which cells were treated with different extract solutions and, if applicable, subjected to NIR irradiation. Images were captured at 0, 12, and 24 h to monitor wound closure. The percentage of wound closure was calculated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\mathrm{S}\mathrm{c}\mathrm{r}\mathrm{a}\mathrm{t}\mathrm{c}\mathrm{h}\:\mathrm{H}\mathrm{e}\mathrm{a}\mathrm{l}\mathrm{i}\mathrm{n}\mathrm{g}\:\left(\mathrm{\%}\right)\:=\frac{S0\:-\:St}{S0}\times\:\:100\mathrm{\%}$$\end{document} where S0 represents the initial scratch area and St represents the scratch area at certain time. Tube formation assay Tube formation assays were performed according to the manufacturer’s instructions. Briefly, 50 µL of Matrigel was added to each well of a 96-well plate and allowed to polymerize. HUVECs were suspended in DMEM and seeded at a density of 2 × 10⁴ cells/well. After 6 h of incubation, the formation of capillary-like structures was observed, and the number of branch points and total tube length were quantified using ImageJ software. Mouse wound healing model and treatment A chronic wound model was established in 8-week-old BALB/c male mice (purchased from China Mouse Biotechnology Co., Ltd.). Diabetes was induced via intraperitoneal injection of streptozotocin (STZ, Selleck, USA) at a dose of 50 mg/kg body weight. Blood glucose levels were measured from the tail vein on days 0, 3, 6, and 7 post-injection using a Bayer Contour Next EZ glucometer (Leverkusen, Germany). Mice with blood glucose levels exceeding 11.1 mmol/L on both day 6 and day 7 were considered diabetic. After anesthesia and hair removal, a full-thickness circular skin wound (10 mm in diameter) was created on the dorsal region of each mouse. A total of 40 mice were randomly divided into five groups: Control (PBS, 0.5 mL), MNs, HMCuS MNs, HMCuS@ISL MNs, and HMCuS@ISL MNs + NIR. Microneedle patches were applied to the wound sites, and NIR irradiation (808 nm laser, 1.0 W/cm², 5 min) was performed every 48 h starting from day 0 post-surgery for the NIR-treated group. Wound images were captured on days 0, 3, 5, 7, 10, and 14 post-surgery. Wound areas were quantified using ImageJ, and the wound healing rate was calculated using the following formula:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\:\mathrm{W}\mathrm{o}\mathrm{u}\mathrm{n}\mathrm{d}\:\mathrm{h}\mathrm{e}\mathrm{a}\mathrm{l}\mathrm{i}\mathrm{n}\mathrm{g}\:\mathrm{r}\mathrm{a}\mathrm{t}\mathrm{e}\:\left(\mathrm{\%}\right)\:=\frac{A0\:-\:A\mathrm{t}}{A0}\times\:\:100\mathrm{\%}$$\end{document} where A0 represents the initial wound area and At represents the wound area at certain time. Histological and immunohistochemical analysis On day 14 post-treatment, mice were euthanized under overdose anesthesia using 4% chloral hydrate. Skin tissues from the wound sites were collected and fixed in 4% paraformaldehyde for 24 h. Fixed tissues were paraffin-embedded and sectioned at 5 μm for subsequent staining. Hematoxylin–eosin (H&E) and Masson’s trichrome staining were performed to assess tissue structure and collagen deposition, respectively. For immunohistochemistry, sections were incubated with primary antibodies against CD31 (1:500, Upingbio) and Ki67 (1:500, Proteintech), followed by DAB visualization and nuclear counterstaining. For immunofluorescence, sections were stained with antibodies against CD68 (1:500, Upingbio), CD206 (1:500, Upingbio), and iNOS (1:500, Upingbio). Five random fields per section were selected for quantitative analysis using ImageJ software. In vitro anti-inflammatory assay RAW264.7 cells were cultured under different conditions for 24 h. Total RNA was extracted, and the expression levels of IL-6, IL-1β, and iNOS were quantified using GAPDH as an internal control. In in vitro mechanistic studies, ISL was applied at a working concentration of 5 µg/mL, which is sufficient to induce significant macrophage polarization from the M1 to the M2 phenotype. Considering that each microneedle patch carries approximately 400 µg of the drug, even accounting for dilution by wound exudate (estimated at 20–50 µL in murine wounds), the local instantaneous concentration at the wound site far exceeds the 5 µg/mL effective threshold. This ensures that potent immune reprogramming can still be achieved in the complex in vivo microenvironment. Western blot (WB) Protein samples were separated on 7% SDS-PAGE gels and transferred onto PVDF membranes. Membranes were blocked with 5% BSA at 25 °C for 2 h, incubated with primary antibodies, and washed with TBST. Protein bands were visualized using an automated chemiluminescence imaging system (Invitrogen iBright 1500, Thermo Fisher) and analyzed with ImageJ software. Quantitative real-time PCR (qRT-PCR) Total RNA was extracted from cells or tissues using TRIzol according to the manufacturer’s instructions. RNA concentration and purity (A260/A280) were measured, and 1 µg RNA was reverse-transcribed into cDNA. Gene expression was quantified using SYBR Green-based qPCR (Applied Biosystems 7500). Primer sequences are provided in Figure S1, with β-actin as the internal control. Each sample was run in triplicate, and three independent experiments were performed. Relative expression levels were calculated using the 2^−ΔΔCt method. Data are presented as mean ± SD, and differences were analyzed using one-way ANOVA followed by Tukey’s post hoc test; P < 0.05 was considered statistically significant. Flow cytometry RAW264.7 cells were stimulated with 1000 ng/mL lipopolysaccharide (LPS, Sigma–Aldrich) and treated with ISL (5 µg/mL) for 24 h. Cells were incubated with CD86-FITC or CD206-FITC antibodies (Biolegend) at 25 °C for 30 min and washed twice with PBS. Macrophage polarization was analyzed by flow cytometry, and data were processed using FlowJo software (Beckman Colter, USA). Seahorse metabolic analysis Treated RAW264.7 cells were seeded into 96-well Seahorse XF plates at 1 × 10⁵ cells/well. Extracellular acidification rate (ECAR) was measured following the addition of glucose (10 mM), oligomycin (2 µM), and 2-deoxy-D-glucose (2-DG, 50 mM). Oxygen consumption rate (OCR) was assessed using oligomycin (2 µM), FCCP (1 µM), and rotenone/antimycin A (0.5 µM). Measurements were conducted with a Seahorse XF96 Extracellular Flux Analyzer according to the manufacturer’s instructions. RNA-Seq analysis RAW264.7 cells were stimulated with LPS (1000 ng/mL) and treated with ISL (5 µg/mL) for 24 h. Total RNA was extracted using TRIzol. RNA concentration and integrity were assessed using a Nanodrop ND-1000 spectrophotometer (Gene Company, USA) and Agilent 2100 Bioanalyzer, respectively. Purified RNA was used for library preparation and sequenced on an Illumina HiSeq X10 platform. Bioinformatic analyses were performed using the NovoMagic cloud platform (Novogene, China) and the Majorbio platform (Majorbio, China). Statistical analysis All experiments were performed at least three times. Data are presented as mean ± SD. Statistical analyses were conducted using GraphPad Prism 9.0. Comparisons between two groups were performed using Student’s t-test, and multiple group comparisons were analyzed by one-way ANOVA followed by Tukey’s post hoc test. P < 0.05 was considered statistically significant. Results Characterization of HMCuS@ISL nanoparticles The morphology of hollow mesoporous copper sulfide (HMCuS) nanoparticles was first examined by transmission electron microscopy (TEM). The results revealed uniform spherical structures with a distinct hollow interior and a porous outer shell (Fig. 1A, B). It should be noted that the loading of ISL did not significantly alter the morphology of the nanostructure, which is consistent with the characteristics of small-molecule incorporation. Dynamic light scattering (DLS) analysis showed that the average hydrodynamic diameter of HMCuS was 248.3 nm with a narrow distribution (PDI = 0.227), which slightly increased to 306.9 nm (PDI = 0.242) after loading ISL (Fig. 1C, D). The zeta potential shifted from −13.1 mV for pristine HMCuS to −9.8 mV for HMCuS@ISL (Fig. 1E), further confirming the successful encapsulation of ISL. Fig. 1Characterizations of HMCuS@ISL nanoparticles. TEM images of (A) HMCuS and (B) HMCuS@ISL nanoparticles. No obvious morphological difference was observed after ISL loading due to its molecular nature. DLS size distribution of (C) HMCuS and (D) HMCuS@ISL nanoparticles. No obvious morphological difference was observed after ISL loading due to its molecular nature. (E) Zeta potentials of HMCuS and HMCuS@ISL nanopartcles. (F) UV-vis spectra of HMCuS at concentrations of 50 µg/mL, 100 µg/mL, 150 µg/mL, and 300 µg/mL. (G) Temperature variation curves of HMCuS (50, 100, 150, and 300 µg/mL) under 808 nm laser irradiation (0.8 W/cm2) during 10 min. (H) UV-vis spectra of HMCuS and HMCuS@ISL. (I) Temperature variation curves of HMCuS and HMCuS@ISL (150 µg/mL) under 808 nm laser irradiation (0.8 W/cm2) for 10 min Characterizations of HMCuS@ISL nanoparticles. TEM images of (A) HMCuS and (B) HMCuS@ISL nanoparticles. No obvious morphological difference was observed after ISL loading due to its molecular nature. DLS size distribution of (C) HMCuS and (D) HMCuS@ISL nanoparticles. No obvious morphological difference was observed after ISL loading due to its molecular nature. (E) Zeta potentials of HMCuS and HMCuS@ISL nanopartcles. (F) UV-vis spectra of HMCuS at concentrations of 50 µg/mL, 100 µg/mL, 150 µg/mL, and 300 µg/mL. (G) Temperature variation curves of HMCuS (50, 100, 150, and 300 µg/mL) under 808 nm laser irradiation (0.8 W/cm2) during 10 min. (H) UV-vis spectra of HMCuS and HMCuS@ISL. (I) Temperature variation curves of HMCuS and HMCuS@ISL (150 µg/mL) under 808 nm laser irradiation (0.8 W/cm2) for 10 min The UV–vis–NIR absorption spectra indicated that HMCuS exhibited a broad absorption band in the near-infrared region, with intensity positively correlated to nanoparticle concentration (Fig. 1F). To evaluate the photothermal conversion capability, aqueous dispersions of HMCuS at different concentrations (50, 100, 150, 300 µg/mL) were irradiated with an 808 nm laser. The temperature elevation was concentration-dependent, whereas the deionized water (DDW) control group exhibited negligible changes (Fig. 1G, Fig. S1). Notably, the temperature of the 300 µg/mL HMCuS dispersion increased to approximately 60 °C within several minutes of irradiation, demonstrating excellent photothermal efficiency. HMCuS@ISL showed similar NIR absorption features to HMCuS (Fig. 1H). Upon 808 nm laser irradiation, both HMCuS and HMCuS@ISL dispersions exhibited concentration-dependent temperature elevation, and the photothermal conversion performance of HMCuS@ISL was comparable to that of pure HMCuS. The time-dependent temperature curves under NIR irradiation (Fig. 1I, Fig. S2) confirmed the pronounced photothermal response of both materials. These findings demonstrate that ISL was successfully loaded into HMCuS nanoparticles without affecting their optical or photothermal properties, providing a solid foundation for subsequent biological investigations. Fabrication and characterization of HMCuS@ISL-loaded microneedle patches To achieve efficient transdermal delivery of HMCuS@ISL nanoparticles, a collagen/hyaluronic acid–based pagoda-like microneedle (MN) patch was fabricated (Fig. 2A). The resulting HMCuS@ISL MNs displayed a well-ordered array with an intact overall structure (Fig. 2B, C). Scanning electron microscopy (SEM) revealed that each needle had a sharp pyramidal shape with smooth surfaces and uniform geometry (Fig. 2D). Fluorescence microscopy further confirmed that the nanoparticles were evenly distributed in the tips of the microneedles (Fig. 2E). Fig. 2Characterizations of HMCuS@ISL MNs. (A) Schematic diagram of HMCuS@ISL MNs preparation. (B) Image of the HMCuS@ISL MNs. (C) Microscopic image of the HMCuS@ISL MNs. (D) SEM image of the HMCuS@ISL MNs. (E) The fluorescence image of the HMCuS@FITC MNs. (F) Force-displacement curve of the HMCuS@ISL MNs. (G) Pinhole blot diagram of the mouse skin after HMCuS@ISL MNs insertion. (H) Dissolution status of the HMCuS@ISL MNs after the insertion of mouse skin at 0 min, 1 min, 3 min, 5 min, and 8 min Characterizations of HMCuS@ISL MNs. (A) Schematic diagram of HMCuS@ISL MNs preparation. (B) Image of the HMCuS@ISL MNs. (C) Microscopic image of the HMCuS@ISL MNs. (D) SEM image of the HMCuS@ISL MNs. (E) The fluorescence image of the HMCuS@FITC MNs. (F) Force-displacement curve of the HMCuS@ISL MNs. (G) Pinhole blot diagram of the mouse skin after HMCuS@ISL MNs insertion. (H) Dissolution status of the HMCuS@ISL MNs after the insertion of mouse skin at 0 min, 1 min, 3 min, 5 min, and 8 min Mechanical testing demonstrated that the load increased linearly with displacement until full penetration (Fig. 2F), indicating sufficient mechanical strength to pierce the skin barrier. Ex vivo porcine skin insertion experiments showed that the MNs could create a uniform array of microchannels upon application, confirming their excellent insertion capability (Fig. 2G). Time-lapse observations revealed that the MNs gradually dissolved within the skin and nearly completely disappeared within 8 min (Fig. 2H), enabling efficient release of HMCuS@ISL. Collectively, these results indicate that the HMCuS@ISL MNs possess desirable morphology, adequate mechanical robustness, and rapid dissolution characteristics suitable for effective transdermal administration. ISL modulates inflammatory and metabolic patterns in macrophages Previous studies using a zebrafish wound model demonstrated that ISL reduced LPS-induced accumulation of ROS and NO in RAW 264.7 cell–derived zebrafish inflammation models, decreased the release of IL-1β, IL-6, and TNF-α [15], and promoted macrophage recruitment and angiogenesis at the wound site, thereby enhancing wound healing [30]. However, the underlying molecular mechanisms remained unclear. To elucidate these mechanisms, RNA sequencing (RNA-seq) was performed on RAW 264.7 cells treated with LPS + ISL (treatment group) or LPS alone (control group). Principal component analysis (PCA) revealed distinct separation between the two groups, suggesting significant transcriptional differences (Fig. 3A). Volcano plot analysis identified 2084 upregulated and 2631 downregulated genes (Fig. 3B). Hierarchical clustering confirmed the markedly distinct gene expression patterns between the groups (Fig. 3C). Fig. 3ISL ameliorates inflammatory and metabolic profiles of macrophages. (A) Principal component analysis (PCA) demonstrating a clear separation between the control and ISL-treated groups. (B) Volcano plot of differentially expressed genes (DEGs) between the two groups. (C) Heatmap clustering of representative DEGs. (D) Gene ontology (GO) enrichment analysis of DEGs highlighting immune regulation, cytokine production, and inflammation-related biological processes. (E) KEGG pathway enrichment analysis indicating the involvement of TNF signaling, NF-κB signaling, cytokine–receptor interactions, and fatty acid metabolism pathways. (F–H) Gene set enrichment analysis (GSEA) plots showing that acute inflammatory response (F) and glycolytic process (G) were significantly downregulated, while fatty acid metabolism was markedly upregulated (H) following ISL treatment ISL ameliorates inflammatory and metabolic profiles of macrophages. (A) Principal component analysis (PCA) demonstrating a clear separation between the control and ISL-treated groups. (B) Volcano plot of differentially expressed genes (DEGs) between the two groups. (C) Heatmap clustering of representative DEGs. (D) Gene ontology (GO) enrichment analysis of DEGs highlighting immune regulation, cytokine production, and inflammation-related biological processes. (E) KEGG pathway enrichment analysis indicating the involvement of TNF signaling, NF-κB signaling, cytokine–receptor interactions, and fatty acid metabolism pathways. (F–H) Gene set enrichment analysis (GSEA) plots showing that acute inflammatory response (F) and glycolytic process (G) were significantly downregulated, while fatty acid metabolism was markedly upregulated (H) following ISL treatment Gene Ontology (GO) enrichment analysis indicated that the differentially expressed genes (DEGs) were primarily associated with immune regulation, cytokine production, inflammatory response, and angiogenesis (Fig. 3D). KEGG pathway analysis revealed enrichment in multiple inflammation- and metabolism-related pathways, including TNF signaling, NF-κB signaling, cytokine–cytokine receptor interaction, and fatty acid metabolism (Fig. 3E). Gene Set Enrichment Analysis (GSEA) further confirmed these findings, showing significant suppression of “positive regulation of acute inflammatory response” (Fig. 3F) and “glycolytic process” (Fig. 3G), while “fatty acid metabolic process” was markedly upregulated (Fig. 3H). Collectively, these results indicate that HMCuS@ISL MNs promote diabetic wound repair by modulating inflammatory responses and reprogramming macrophage metabolism. ISL promotes macrophage polarization from pro-inflammatory to anti-inflammatory phenotypes via metabolic reprogramming Analysis of macrophage M1/M2 polarization Macrophages play a pivotal regulatory role in wound healing. Early-stage M1 macrophages mediate inflammatory clearance of necrotic tissue, while later transition to M2 macrophages promotes angiogenesis and tissue regeneration. Failure of the M1-to-M2 transition leads to persistent inflammation and delayed wound closure [8, 31]. Previous studies have shown that ISL suppresses LPS-induced ROS and NO accumulation in RAW 264.7 cells, inhibits NF-κB p65 nuclear translocation, and decreases IL-1β, IL-6, and TNF-α secretion [15]. Moreover, ISL inhibits both the protein and mRNA expression of iNOS and COX-2 in LPS-stimulated macrophages [32]. To further elucidate the immunoregulatory mechanisms of ISL, macrophage polarization was assessed in vitro. RNA-seq results indicated that ISL treatment significantly downregulated pro-inflammatory (M1) genes IL-6, Ccr7, Il1b, and Nos2, while markedly upregulating anti-inflammatory (M2) genes Mrc1, Il10, and Arg1 (Fig. 4A). Quantitative PCR confirmed that LPS strongly upregulated glycolysis-related genes (HK1, HK2, PFKP, PKM, SLC2A1) while downregulating fatty acid synthesis (FASN) and fatty acid oxidation (CPT1A) genes, trends that were reversed by ISL treatment (Fig. 4B). Flow cytometry further validated this shift: LPS stimulation increased the proportion of CD86⁺ (M1) macrophages and decreased CD206⁺ (M2) cells, whereas ISL treatment restored the M1/M2 balance (Fig. 4C). Consistently, qPCR analysis showed that LPS markedly upregulated IL-6, IL-1β, and iNOS mRNA levels, which were significantly reduced upon ISL treatment (Fig. 4D–F). Fig. 4ISL reprograms macrophage metabolism to shift polarization from pro-inflammatory to anti-inflammatory phenotypes. (A) RNA-seq analysis of M1/M2 polarization-associated genes (IL6, Ccr7, Il1b, Nos2, MRC1, IL10, Arg1) (B) RNA-seq analysis of glycolysis- and fatty acid metabolism-related genes (HK1, HK2, PFKP, PKM, Slc2a1, Fasn, Cpt1a). (C) Flow cytometry analysis and quantification of CD86 (M1) and CD206 (M2) macrophage populations. (D–F) qPCR quantification of inflammatory cytokines IL6, IL1β, and Nos2 under different treatments (G–H) Western blot analysis and quantification of glycolysis- and fatty acid metabolism-associated proteins (HK1, HK2, PFKP, PKM, SLC2A1, CPT1A). (I) Extracellular acidification rate (ECAR) and (J) oxygen consumption rate (OCR) measured by seahorse analysis, demonstrating metabolic reprogramming of macrophages ISL reprograms macrophage metabolism to shift polarization from pro-inflammatory to anti-inflammatory phenotypes. (A) RNA-seq analysis of M1/M2 polarization-associated genes (IL6, Ccr7, Il1b, Nos2, MRC1, IL10, Arg1) (B) RNA-seq analysis of glycolysis- and fatty acid metabolism-related genes (HK1, HK2, PFKP, PKM, Slc2a1, Fasn, Cpt1a). (C) Flow cytometry analysis and quantification of CD86 (M1) and CD206 (M2) macrophage populations. (D–F) qPCR quantification of inflammatory cytokines IL6, IL1β, and Nos2 under different treatments (G–H) Western blot analysis and quantification of glycolysis- and fatty acid metabolism-associated proteins (HK1, HK2, PFKP, PKM, SLC2A1, CPT1A). (I) Extracellular acidification rate (ECAR) and (J) oxygen consumption rate (OCR) measured by seahorse analysis, demonstrating metabolic reprogramming of macrophages Metabolic reprogramming and energy status Because macrophage polarization is tightly coupled to metabolic reprogramming—M1 macrophages predominantly relying on glycolysis and M2 macrophages favoring oxidative phosphorylation and fatty acid oxidation [33, 34]—we next examined the relevant metabolic markers. Western blot analysis showed that LPS stimulation enhanced the expression of glycolytic enzymes (HK1, HK2, PFKP, PKM, SLC2A1) and suppressed CPT1A, whereas HMCuS@ISL treatment reversed these effects (Fig. 4G–H). Extracellular flux analysis revealed that LPS elevated both extracellular acidification rate (ECAR) and oxygen consumption rate (OCR), while ISL significantly normalized glycolytic and mitochondrial oxidative activity (Fig. 4I–J). Taken together, these findings demonstrate that ISL reshapes cellular energy metabolism to promote M2 polarization and suppress inflammatory activation, thereby contributing to wound resolution and tissue repair. Biocompatibility and cytocompatibility of HMCuS@ISL microneedles To evaluate the cytocompatibility of HMCuS@ISL microneedle (MN) patches, the proliferation and viability of human umbilical vein endothelial cells (HUVECs) and fibroblasts (NIH-3T3) under various treatments were examined. CCK-8 assays demonstrated that blank MNs, HMCuS MNs, HMCuS@ISL MNs, and HMCuS@ISL MNs combined with near-infrared (NIR) irradiation exhibited no significant cytotoxicity (Fig. 5A, B), indicating excellent biocompatibility. Fig. 5In vitro biocompatibility evaluation of HMCuS@ISL microneedles. (A, B) CCK-8 assay of HUVEC (A) and NIH-3T3 (B) cell proliferation on days 1, 3, and 5 under different treatments. (C) Live/dead staining of HUVECs after treatment with extracts of MNs, HMCuS MNs, HMCuS@ISL MNs, and HMCuS@ISL MNs + NIR (live cells in green, dead cells in red). (D) Live/dead staining of NIH-3T3 fibroblasts under identical treatment conditions. Data are presented as mean ± SD (n = 5) In vitro biocompatibility evaluation of HMCuS@ISL microneedles. (A, B) CCK-8 assay of HUVEC (A) and NIH-3T3 (B) cell proliferation on days 1, 3, and 5 under different treatments. (C) Live/dead staining of HUVECs after treatment with extracts of MNs, HMCuS MNs, HMCuS@ISL MNs, and HMCuS@ISL MNs + NIR (live cells in green, dead cells in red). (D) Live/dead staining of NIH-3T3 fibroblasts under identical treatment conditions. Data are presented as mean ± SD (n = 5) Live/dead staining further confirmed these findings: nearly all HUVECs (Fig. 5C) and NIH-3T3 cells (Fig. 5D) displayed green fluorescence (live cells) with minimal red fluorescence (dead cells), with no significant differences among groups. These results demonstrate that HMCuS@ISL MNs do not adversely affect cell viability or proliferation, providing a favorable safety profile for subsequent in vivo applications. HMCuS@ISL microneedles combined with nir irradiation promote in vitro endothelial cell migration and angiogenesis Fibroblast migration and angiogenesis of HUVECs are essential for wound repair, facilitating oxygen and nutrient supply and removal of metabolic waste, thereby promoting tissue regeneration and accelerating healing [35–37]. Previous studies reported that ISL promotes macrophage recruitment and angiogenesis at wound sites [30], while HMCuS exhibits ROS-scavenging and Cu⁺-Cu-releasing properties that may contribute to angiogenesis [26]. Based on these findings, we hypothesized that HMCuS@ISL possesses synergistic proangiogenic effects. To assess the impact of HMCuS@ISL MNs on fibroblast function, a scratch wound assay was performed using extract solutions from various MN formulations (1 mL/well). The HMCuS@ISL MNs + NIR group was subjected to laser irradiation (808 nm, 1 W/cm², 5 min). As shown in Fig. 6A, the scratch closure rates in the HMCuS@ISL MNs and HMCuS@ISL MNs + NIR groups were significantly higher than those in the control, MNs, and HMCuS MNs groups. Quantitative analysis revealed that at 12 and 24 h, cell migration rates in these two groups were markedly elevated compared to others (Fig. 6C–D, ***p < 0.001). Fig. 6HMCuS@ISL microneedles combined with NIR irradiation enhance endothelial cell migration and angiogenesis in vitro. (A) Representative images of HUVEC scratch wound healing assays at 0, 12, and 24 h (control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). (B) The lower row displays the corresponding quantitative analysis results processed by ImageJ software (Angiogenesis Analyzer plugin). Specifically, the red lines (Segments) represent the effective tubular branches formed; the yellow/green dots (Junctions/Nodes) indicate the intersection points of these branches; and the blue enclosed areas (Meshes) represent the organized and mature vascular network structures. (C, D) Quantitative analysis of cell migration rates at 12 h and 24 h. (E, F) Quantification of the number of junctions and total tube length. Data are presented as mean ± SD (n = 5). ns, not significant; **p < 0.01, ***p < 0.001 HMCuS@ISL microneedles combined with NIR irradiation enhance endothelial cell migration and angiogenesis in vitro. (A) Representative images of HUVEC scratch wound healing assays at 0, 12, and 24 h (control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). (B) The lower row displays the corresponding quantitative analysis results processed by ImageJ software (Angiogenesis Analyzer plugin). Specifically, the red lines (Segments) represent the effective tubular branches formed; the yellow/green dots (Junctions/Nodes) indicate the intersection points of these branches; and the blue enclosed areas (Meshes) represent the organized and mature vascular network structures. (C, D) Quantitative analysis of cell migration rates at 12 h and 24 h. (E, F) Quantification of the number of junctions and total tube length. Data are presented as mean ± SD (n = 5). ns, not significant; **p < 0.01, ***p < 0.001 Similarly, HUVEC tube formation assays demonstrated that both HMCuS@ISL MNs and HMCuS@ISL MNs + NIR groups formed denser, more branched capillary-like networks (Fig. 6B). Statistical analysis confirmed significantly greater node numbers and total tube lengths in these groups (Fig. 6E–F, **p < 0.01, ***p < 0.001). Collectively, these findings indicate that HMCuS@ISL MNs, with or without NIR irradiation, effectively promote endothelial cell migration and angiogenesis, providing a cellular basis for enhanced wound repair. Antibacterial activity of HMCuS@ISL microneedles combined with NIR irradiation To evaluate antibacterial efficacy, Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus), representative pathogens of infected diabetic wounds [38], were selected. It has been reported that HMCuS exhibits enhanced antibacterial effects via NIR-triggered photothermal conversion [39]. To further assess the antibacterial performance of HMCuS@ISL MNs, both Gram-negative (E. coli) and Gram-positive (S. aureus) bacterial models were utilized. As shown in Fig. 7A, both HMCuS MNs and HMCuS@ISL MNs exhibited moderate antibacterial effects, while the HMCuS@ISL MNs + NIR group showed a marked reduction in bacterial colony numbers. Live/dead bacterial staining further confirmed this observation, with a significant increase in red/yellow fluorescence (dead bacteria) in the HMCuS@ISL MNs + NIR group compared with the control, MNs, and HMCuS MNs groups (Fig. 7B). Colony-forming unit (CFU) assays corroborated these findings, showing that although HMCuS@ISL MNs alone significantly reduced bacterial counts, the HMCuS@ISL MNs + NIR group exhibited the most pronounced antibacterial effect against both E. coli and S. aureus (Fig. 7C–D, **p < 0.01, ***p < 0.001). These results suggest that NIR-triggered photothermal activation significantly enhances the bactericidal performance of HMCuS@ISL MNs, consistent with previous reports. Furthermore, bacterial growth curves revealed that after 24 h, the HMCuS@ISL MNs + NIR group exhibited the strongest inhibitory effect on bacterial proliferation (Fig. 7E–F). Taken together, these data demonstrate that HMCuS@ISL MNs combined with NIR irradiation exhibit potent broad-spectrum antibacterial activity against both Gram-negative and Gram-positive bacteria. Fig. 7Antibacterial activity of HMCuS@ISL microneedles combined with NIR irradiation. (A) Representative colony images of E. coli and S. aureus under different treatments (control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). (B) Confocal images of live/dead-stained bacteria (green: live, red: dead). (C, D) Quantitative CFU counts of E. coli and S. aureus. (E, F) Bacterial growth curves (OD600) showing growth trends over 24 h. Data are presented as mean ± SD (n = 5). ns, Not significant; **p < 0.01, ***p < 0.001 Antibacterial activity of HMCuS@ISL microneedles combined with NIR irradiation. (A) Representative colony images of E. coli and S. aureus under different treatments (control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). (B) Confocal images of live/dead-stained bacteria (green: live, red: dead). (C, D) Quantitative CFU counts of E. coli and S. aureus. (E, F) Bacterial growth curves (OD600) showing growth trends over 24 h. Data are presented as mean ± SD (n = 5). ns, Not significant; **p < 0.01, ***p < 0.001 HMCuS@ISL microneedles combined with NIR irradiation accelerate wound healing in diabetic mice To verify the in vivo wound healing efficacy of HMCuS@ISL microneedles, a streptozotocin (STZ)-induced diabetic mouse wound model was established, as illustrated in Fig. 8A. Representative wound images showed delayed closure and pronounced scab formation in the control and MNs groups, while partial improvement was observed in the HMCuS MNs and HMCuS@ISL MNs groups (Fig. 8B). Notably, the HMCuS@ISL MNs + NIR group exhibited the most rapid healing, with evident wound contraction by day 7 and nearly complete closure by day 14. Quantitative analysis revealed that the wound areas in the HMCuS@ISL MNs + NIR group were significantly smaller than those in other groups on days 7, 10, and 14 (Fig. 8C, *p < 0.05, ***p < 0.001). These findings demonstrate that HMCuS@ISL microneedles combined with NIR irradiation markedly accelerate the wound healing process in diabetic mice. Fig. 8HMCuS@ISL microneedles promote diabetic wound closure in vivo. (A) Schematic illustration of the experimental procedure: STZ-induced diabetic mice with 10 mm full-thickness skin defects were treated with different microneedle patches and monitored for 14 days. (B) Representative wound images of each group (Control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR) on days 0, 3, 7, 10, and 14, with corresponding wound area diagrams on the right. (C) Quantitative analysis of wound closure rates over time. Data are presented as mean ± SD (n = 5). *p < 0.05, ***p < 0.001 HMCuS@ISL microneedles promote diabetic wound closure in vivo. (A) Schematic illustration of the experimental procedure: STZ-induced diabetic mice with 10 mm full-thickness skin defects were treated with different microneedle patches and monitored for 14 days. (B) Representative wound images of each group (Control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR) on days 0, 3, 7, 10, and 14, with corresponding wound area diagrams on the right. (C) Quantitative analysis of wound closure rates over time. Data are presented as mean ± SD (n = 5). *p < 0.05, ***p < 0.001 To further evaluate the biosafety of the microneedle treatments, body weights of mice from different groups were monitored over the 14-day treatment period. As shown in Figure S4, all groups exhibited a gradual increase in body weight without significant intergroup differences, indicating good overall health and tolerance to treatment. These results suggest that topical application of HMCuS@ISL microneedle patches, with or without NIR irradiation, induces no systemic toxicity or adverse effects on animal growth. Pain is a common complication of wounds; therefore, the mouse grimace scale (MGS) was used to assess pain levels across groups. As shown in Figure S5, MGS scores were comparable among all groups prior to treatment (day 0), indicating similar baseline pain. Over time, MGS scores gradually decreased in all groups, reflecting progressive pain relief during healing. Remarkably, mice in the HMCuS@ISL MNs + NIR group exhibited significantly lower MGS scores on days 2 and 3 compared with other groups (*p < 0.05), suggesting a superior analgesic effect. It is noteworthy that the MGS score, as a behavioral indicator, may be influenced by multiple factors. In particular, during the early stages of treatment, NIR-induced photothermal effects could transiently modulate local neural activity, potentially affecting facial expression scoring. Additionally, the anti-inflammatory effects of ISL may indirectly alleviate pain by reducing the local inflammatory response. Therefore, the observed analgesic effects likely reflect the combined action of multiple factors, and the underlying mechanisms require further investigation to be fully elucidated. Collectively, these results indicate that the HMCuS@ISL microneedle patch combined with NIR irradiation not only accelerates wound closure but also effectively alleviates pain, underscoring its therapeutic potential in diabetic wound management. Histological and immunohistochemical analysis of wound healing under different microneedle treatments To evaluate the histological effects of different treatments on diabetic wound repair, hematoxylin and eosin (H&E) and Masson’s trichrome staining were performed (Fig. 9A). The control and MNs groups exhibited incomplete epithelial coverage and disorganized collagen deposition, while partial re-epithelialization and tissue regeneration were observed in the HMCuS MNs group. The HMCuS@ISL MNs group showed markedly thickened epidermis and more orderly collagen arrangement. Notably, in the presence of NIR irradiation, the HMCuS@ISL MNs + NIR group achieved nearly complete epidermal regeneration and dense collagen deposition, indicating optimal wound closure and extracellular matrix remodeling. Fig. 9Histological and immunohistochemical evaluation of diabetic wound tissues after treatment with different microneedle patches. (A) Representative H&E and Masson’s trichrome staining images of wound tissues from each group (Control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). Scale bar = 200 μm. (B) Immunohistochemical staining for CD31 and Ki-67 to assess angiogenesis and cell proliferation. Scale bar = 50 μm. (C) Quantification of neocapillary density. (D, E) Quantification of epithelial (D) and dermal (E) cell proliferation rates Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, NS = not significant Histological and immunohistochemical evaluation of diabetic wound tissues after treatment with different microneedle patches. (A) Representative H&E and Masson’s trichrome staining images of wound tissues from each group (Control, MNs, HMCuS MNs, HMCuS@ISL MNs, HMCuS@ISL MNs + NIR). Scale bar = 200 μm. (B) Immunohistochemical staining for CD31 and Ki-67 to assess angiogenesis and cell proliferation. Scale bar = 50 μm. (C) Quantification of neocapillary density. (D, E) Quantification of epithelial (D) and dermal (E) cell proliferation rates Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, NS = not significant Immunohistochemical staining for CD31 and Ki-67 (Fig. 9B) revealed enhanced angiogenesis and cell proliferation in the HMCuS@ISL MNs group, reaching maximal levels in the HMCuS@ISL MNs + NIR group. Quantitative analysis further confirmed this trend: capillary density (Fig. 9C) and epidermal/dermal proliferation indices (Fig. 9D–E) were significantly higher in the HMCuS@ISL MNs + NIR group than in other groups (p < 0.001). These findings suggest that this combinatorial treatment promotes superior wound healing in diabetic mice by synergistically enhancing angiogenesis and tissue regeneration. Immunoregulatory effects of different microneedle treatments on macrophage polarization in diabetic wounds To further investigate the immunomodulatory effects of different treatments on macrophage polarization within diabetic wounds, immunofluorescence staining for M1 (CD86/iNOS) and M2 (CD68/CD206) markers was performed on wound tissues at days 3 and 7 post-injury. As shown in Fig. 10A, abundant CD86⁺iNOS⁺ M1 macrophages were present in the control and MNs groups, indicating a persistent pro-inflammatory state. The infiltration of M1 macrophages decreased slightly in the HMCuS MNs group and significantly in the HMCuS@ISL MNs group. Strikingly, the HMCuS@ISL MNs + NIR group exhibited the most pronounced reduction in M1 macrophages, suggesting effective suppression of excessive inflammation. Fig. 10Immunomodulatory effects of different microneedle patches on macrophage polarization in diabetic wounds. (A) Immunofluorescence staining of M1 macrophage markers (CD68, red; iNOS, green) at days 3 and 7 post-injury. Scale bar = 50 μm. (B) Immunofluorescence staining of M2 macrophage markers (CD68, red; CD206, green) at days 3 and 7 post-injury. Scale bar = 50 μm. (C, D) Quantification of CD68⁺iNOS⁺ M1 macrophages (C) and CD68⁺CD206⁺ M2 macrophages (D) in each group. Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant Immunomodulatory effects of different microneedle patches on macrophage polarization in diabetic wounds. (A) Immunofluorescence staining of M1 macrophage markers (CD68, red; iNOS, green) at days 3 and 7 post-injury. Scale bar = 50 μm. (B) Immunofluorescence staining of M2 macrophage markers (CD68, red; CD206, green) at days 3 and 7 post-injury. Scale bar = 50 μm. (C, D) Quantification of CD68⁺iNOS⁺ M1 macrophages (C) and CD68⁺CD206⁺ M2 macrophages (D) in each group. Data are presented as mean ± SD (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant In contrast, immunofluorescence staining for CD68⁺, CD206⁺ M2 macrophages (Fig. 10B) revealed enhanced M2 recruitment in the HMCuS@ISL MNs group compared with the control, MNs, and HMCuS MNs groups. This effect was further amplified under NIR irradiation, with markedly increased M2 macrophage accumulation observed at both day 3 and day 7. Quantitative analysis confirmed that the HMCuS@ISL MNs + NIR group exhibited a significant reduction in M1 macrophage ratio, accompanied by a robust enhancement in M2 polarization (Fig. 10C–D, p < 0.001). Collectively, these results demonstrate that the combined HMCuS@ISL MNs + NIR treatment not only mitigates inflammatory responses but also establishes a pro-regenerative immune microenvironment, thereby facilitating efficient diabetic wound healing. In vivo systemic biosafety evaluation To comprehensively assess the systemic biosafety of HMCuS@ISL microneedle patches and their NIR-assisted therapy, hematological and serum biochemical analyses were conducted. As shown in Figure S6, there were no significant differences among the control, MNs, and HMCuS@ISL MNs + NIR groups in hematological parameters, including white blood cell count (WBC), red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet count (PLT), red cell distribution width (RDW-SD), and mean platelet volume (MPV). Similarly, serum biochemical indices—alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CREA), and urea (UREA)—remained within normal ranges, indicating no hepatic or renal dysfunction. Histological examination (H&E staining) of major organs (heart, liver, spleen, lung, and kidney) further confirmed the absence of pathological alterations (Fig. S7). Specifically, myocardial fibers were intact without necrosis or inflammatory infiltration; hepatocytes exhibited normal morphology with clearly defined hepatic cords and no fatty degeneration or necrosis; splenic architecture was preserved with distinct red and white pulp regions; lung tissue showed intact alveolar structures without exudation or hemorrhage; and renal glomeruli and tubules maintained normal architecture without edema or cellular damage. These findings collectively demonstrate that HMCuS@ISL microneedle patches, even under NIR irradiation, exert no adverse effects on hematopoietic, hepatic, or renal systems, and cause no histopathological injury to major organs—confirming excellent biocompatibility and systemic biosafety in vivo. Discussion Wound healing is a highly dynamic and multistage biological process involving inflammation, cell migration, angiogenesis, and tissue remodeling [2, 40, 41]. In chronic or infected wounds, excessive oxidative stress, bacterial invasion, and a sustained inflammatory microenvironment disrupt the normal healing rhythm, leading to delayed tissue regeneration [42, 43]. In recent years, smart-responsive wound therapies have shown distinct advantages in regulating the wound microenvironment. Multifunctional platforms that integrate drug delivery with physical stimulation (e.g., photothermal or photodynamic effects) have emerged as promising strategies for precise and efficient tissue repair [44, 45]. The HMCuS@ISL microneedle system (HMCuS@ISL MNs) designed in this study was developed based on this concept, enabling photothermal-responsive drug release and microenvironmental modulation to achieve synergistic antibacterial, anti-inflammatory, and pro-regenerative effects. From a physicochemical perspective, HMCuS nanoparticles exhibit a typical hollow and porous architecture, which not only facilitates efficient drug loading and stable storage but also provides abundant interfacial sites for photothermal conversion. Under near-infrared (NIR) irradiation, HMCuS rapidly converts light energy into heat, generating a mild and controllable local thermal effect. On one hand, this photothermal effect can directly disrupt bacterial membranes and inhibit biofilm formation; on the other, localized heating accelerates blood flow and cellular metabolism, thereby improving wound microcirculation. Moreover, copper ions (Cu²⁺) at appropriate concentrations can promote endothelial cell migration and tubulogenesis, further enhancing revascularization. Consistent with previous reports on CuS-based photothermal nanomaterials, the present study demonstrated that HMCuS@ISL exhibits excellent antibacterial activity and proangiogenic capability under light irradiation. It is important to note that the safety of photothermal therapy is critical for practical applications. In this study, NIR irradiation parameters were optimized to achieve effective antibacterial activity while minimizing thermal damage to surrounding healthy tissues. Although elevated temperatures can be observed in vitro at higher nanoparticle concentrations, local temperatures in vivo are generally maintained within a mild range due to tissue heat dissipation and blood flow regulation, thereby reducing the risk of thermal injury. Future studies should incorporate techniques such as infrared thermography to dynamically monitor local wound temperatures and further evaluate long-term biosafety, thereby facilitating clinical translation of this approach. ISL, a naturally derived flavonoid compound, also plays a crucial biological role in this system. ISL has been reported to suppress inflammation and promote tissue regeneration by modulating the nuclear translocation of NF-κB p65 and regulating the Raf/MEK signaling pathway [15, 16]. In the present study, our results suggest that ISL facilitates wound repair by modulating the immunometabolic state of macrophages. RNA-seq analysis revealed significant enrichment of signaling pathways related to inflammation regulation and metabolism following ISL treatment, while metabolic flux assays further confirmed that ISL modulates both glycolysis and oxidative phosphorylation in macrophages. In vivo experiments demonstrated increased expression of M2 macrophage markers, accompanied by enhanced angiogenesis and accelerated wound healing. Collectively, these findings indicate that immunometabolic reprogramming of macrophages may play a key role in the therapeutic effects of ISL. It should be noted, however, that the causal relationship has not yet been fully verified, as macrophage depletion or metabolic inhibition experiments were not performed in this study. Future investigations will employ macrophage-specific interventions or metabolic modulation strategies to further elucidate the underlying mechanisms. Compared with conventional antibacterial dressings or single-agent delivery systems, the HMCuS@ISL microneedle platform offers several distinct advantages. First, the microneedle structure enables precise transdermal penetration through the stratum corneum, achieving targeted drug delivery and deep tissue action while avoiding the diffusion barriers of traditional topical formulations. Second, the photothermal responsiveness confers a “physical antibacterial” mechanism, reducing the risk of antibiotic resistance. Third, the biocompatibility and biodegradability of the microneedle material ensure safety during use, laying a solid foundation for clinical translation. Importantly, compared with previously reported MN–PTT systems that rely primarily on photothermal antibacterial effects, the superior therapeutic efficacy of HMCuS@ISL MNs is attributed not to a single mechanism but to the synergistic combination of multiple effects. The photothermal response contributes to rapid bacterial eradication and microcirculatory improvement; ISL exerts anti-inflammatory and pro-angiogenic effects; and Cu²⁺ ions further promote neovascularization and matrix remodeling. This “multi-mechanism synergy” strategy breaks the limitations of conventional single-agent or single-material therapies, representing a new paradigm in the development of wound-healing biomaterials. For example, Chuankai Zhang et al. synthesized silk fibroin-templated copper sulfide nanoparticles functionalized with a tannic acid–iron (TA–Fe) metal–phenolic network (CuS-Se@TA–Fe NPs) for catalytic antibacterial therapy [46]. Similarly, Qinghua Li et al. developed an EGCG–Cu capsule hydrogel system (EGCG–Cu@CB gel) that demonstrated enhanced healing of infected wounds through combined antibacterial and anti-inflammatory actions [47]. Building upon these advances, our study further establishes a wearable microneedle-based platform with immunomodulatory functionality, offering greater operational convenience and clinical potential. Nevertheless, several limitations should be acknowledged. The pagoda-like microneedle design enhances structural stability and may facilitate rapid dissolution and drug release, although no systematic comparison with other geometries was conducted. Photothermal parameters must be precisely controlled to avoid thermal damage, and the pharmacokinetics of ISL within complex wound environments require further investigation. The HMCuS@ISL system integrates photothermal antibacterial activity with immunometabolic regulation, achieving superior wound healing compared with single treatments; however, definitive synergistic effects remain to be validated due to the lack of temperature-matched or functional inhibition studies. Mechanistically, our findings suggest that ISL promotes macrophage immunometabolic reprogramming, supported by transcriptomic, metabolic, and polarization analyses, although further studies on cytokine networks, immune cell interactions, and vascular stability are needed. Additionally, while effective local delivery was observed, ISL release kinetics have not been systematically evaluated under physiological conditions, and NIR irradiation may influence drug diffusion and release behavior. Future work should therefore focus on comprehensive mechanistic validation and quantitative assessment of spatiotemporal drug release under physiologically relevant conditions to facilitate clinical translation. Conclusion In summary, this study successfully constructed an HMCuS@ISL-loaded pagoda-like microneedle system that operates via a photothermal antibacterial–metabolic reprogramming mechanism. This approach demonstrates synergistic efficacy in eradicating bacteria, resolving inflammation, promoting M2 macrophage polarization, and enhancing angiogenesis. Our findings present a novel therapeutic concept and an advanced material design for the treatment of complex diabetic wounds. This work underscores the significant potential of intelligent, photothermal-drug co-delivery microneedle systems in regenerative medicine and the management of infected chronic wounds. Supplementary Information Supplementary Material 1 Supplementary Material 1